Stephen J Kent

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6481835/publications.pdf

Version: 2024-02-01

371 papers	20,176 citations	18436 62 h-index	20307 116 g-index
409 all docs	409 docs citations	409 times ranked	23714 citing authors

#	Article	IF	Citations
1	Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 1205-1211.	15.2	3,133
2	Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nature Microbiology, 2020, 5, 1185-1191.	5.9	553
3	Long-lived epithelial immunity by tissue-resident memory T (T _{RM}) cells in the absence of persisting local antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7037-7042.	3.3	522
4	Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nature Immunology, 2022, 23, 210-216.	7.0	486
5	Minimum information reporting in bioâ€“nano experimental literature. Nature Nanotechnology, 2018, 13, 777-785.	15.6	455
6	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe, The, 2022, 3, e52-e61.	3.4	436
7	Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nature Medicine, 2020, 26, 1428-1434.	15.2	400
8	Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nature Communications, 2021, 12, 1162.	5.8	316
9	Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus. Journal of Virology, 1998, 72, 10180-10188.	1.5	310
10	Butyrophilin 2A1 is essential for phosphoantigen reactivity by Î³Î´ T cells. Science, 2020, 367, .	6.0	275
11	Tuberculous Meningitis: A 30-Year Review. Clinical Infectious Diseases, 1993, 17, 987-994.	2.9	237
12	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nature Reviews Immunology, 2021, 21, 395-404.	10.6	223
13	Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity Antibodies in the Absence of Neutralizing Antibodies. Journal of Immunology, 2013, 190, 1837-1848.	0.4	200
14	Circulating T _{FH} cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Science Translational Medicine, 2018, 10, .	5.8	196
15	Cytotoxic CD4 T Cellsâ€”Friend or Foe during Viral Infection?. Frontiers in Immunology, 2017, 8, 19.	2.2	177
16	A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell, 2019, 177, 1136-1152.e18.	13.5	177
17	A Protective Vaccine Delivery System for In Vivo T Cell Stimulation Using Nanoengineered Polymer Hydrogel Capsules. ACS Nano, 2009, 3, 3391-3400.	7.3	170
18	Antibody-Dependent Cellular Cytotoxicity Is Associated with Control of Pandemic H1N1 Influenza Virus Infection of Macaques. Journal of Virology, 2013, 87, 5512-5522.	1.5	168

#	Article	IF	Citations
19	Suboptimal SARS-CoV-2â"specific CD8 ⁺ T cell response associated with the prominent HLA-A*02:01 phenotype. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 24384-24391.	3.3	168
20	Rapid Viral Escape at an Immunodominant Simian-Human Immunodeficiency Virus Cytotoxic T-Lymphocyte Epitope Exacts a Dramatic Fitness Cost. Journal of Virology, 2005, 79, 5721-5731.	1.5	164
21	Binding, Internalization, and Antigen Presentation of Vaccineâ€Loaded Nanoengineered Capsules in Blood. Advanced Materials, 2008, 20, 4698-4703.	11.1	155
22	High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40). Journal of Immunology, 2009, 183, 2827-2836.	0.4	153
23	Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery. ACS Nano, 2017, 11, 54-68.	7.3	153
24	Engineering Poly(ethylene glycol) Particles for Improved Biodistribution. ACS Nano, 2015, 9, 1571-1580.	7.3	148
25	From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. Acta Biomaterialia, 2021, 131, 16-40.	4.1	140
26	Specific antibodyâ€dependent cellular cytotoxicity responses associated with slow progression of <scp>HIV</scp> infection. Immunology, 2013, 138, 116-123.	2.0	139
27	Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7505-7510.	3.3	135
28	Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. Cell Reports, 2021, 34, 108684.	2.9	134
29	A paradigm for peptide vaccine delivery using viral epitopes encapsulated in degradable polymer hydrogel capsules. Biomaterials, 2009, 30, 5178-5186.	5.7	126
30	Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nature Communications, 2021, 12, 2037.	5.8	125
31	Role of IgG3 in Infectious Diseases. Trends in Immunology, 2019, 40, 197-211.	2.9	123
32	Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Reports Medicine, 2021, 2, 100208.	3.3	115
33	Influenza-Specific Antibody-Dependent Cellular Cytotoxicity: Toward a Universal Influenza Vaccine. Journal of Immunology, 2014, 193, 469-475.	0.4	112
34	Activation of NK Cells by ADCC Antibodies and HIV Disease Progression. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, 127-131.	0.9	109
35	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	109
36	Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine. ACS Nano, 2022, 16, 11769-11780.	7.3	108

#	Article	IF	Citations
37	Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models. Nature Reviews Immunology, 2020, 20, 727-738.	10.6	107
38	CD8+ TÂcells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity. Immunity, 2021, 54, 1066-1082.e5.	6.6	106
39	Rapid Degranulation of NK Cells following Activation by HIV-Specific Antibodies. Journal of Immunology, 2009, 182, 1202-1210.	0.4	103
40	Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. European Respiratory Journal, 2021, 57, 2003730.	3.1	100
41	Immunological basis for enhanced immunity of nanoparticle vaccines. Expert Review of Vaccines, 2019, 18, 269-280.	2.0	97
42	Robust NK Cell-Mediated Human Immunodeficiency Virus (HIV)-Specific Antibody-Dependent Responses in HIV-Infected Subjects. Journal of Virology, 2008, 82, 5450-5459.	1.5	95
43	Simian Immunodeficiency Virus Infects Follicular Helper CD4 T Cells in Lymphoid Tissues during Pathogenic Infection of Pigtail Macaques. Journal of Virology, 2013, 87, 3760-3773.	1.5	94
44	Functional cure of HIV: the scale of the challenge. Nature Reviews Immunology, 2019, 19, 45-54.	10.6	93
45	Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast?. Nature Reviews Immunology, 2022, 22, 387-397.	10.6	93
46	HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Daysâ€"Implications for HIV Remission. PLoS Pathogens, 2015, 11, e1005000.	2.1	92
47	MAIT cells are depleted early but retain functional cytokine expression in HIV infection. Immunology and Cell Biology, 2015, 93, 177-188.	1.0	90
48	Dimeric FcÎ³R Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG. Journal of Immunology, 2016, 197, 1507-1516.	0.4	90
49	Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunological Reviews, 1999, 171, 27-44.	2.8	88
50	Mechanically Tunable, Selfâ€Adjuvanting Nanoengineered Polypeptide Particles. Advanced Materials, 2013, 25, 3468-3472.	11.1	84
51	Influenza lineage extinction during the COVID-19 pandemic?. Nature Reviews Microbiology, 2021, 19, 741-742.	13.6	82
52	Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem. Journal of Clinical Investigation, 2019, 129, 850-862.	3.9	78
53	Efficacy of DNA and Fowlpox Virus Priming/Boosting Vaccines for Simian/Human Immunodeficiency Virus. Journal of Virology, 2004, 78, 13819-13828.	1.5	77
54	Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. Aids, 1997, 11, 1565-1574.	1.0	76

#	Article	IF	Citations
55	Reduced Hepatitis B Virus (HBV)-Specific CD4 + T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy. Journal of Virology, 2005, 79, 3038-3051.	1.5	76
56	Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and nonâ€human primates. European Journal of Immunology, 2015, 45, 854-864.	1.6	76
57	Immune imprinting and SARS-CoV-2 vaccine design. Trends in Immunology, 2021, 42, 956-959.	2.9	73
58	Analysis of Pigtail Macaque Major Histocompatibility Complex Class I Molecules Presenting Immunodominant Simian Immunodeficiency Virus Epitopes. Journal of Virology, 2005, 79, 684-695.	1.5	71
59	Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. Journal of Clinical Investigation, 2018, 129, 182-191.	3.9	69
60	What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine, 2016, 8, 277-290.	2.7	67
61	A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA. Nature Communications, 2018, 9, 2669.	5.8	67
62	Cellular Interactions of Liposomes and PISA Nanoparticles during Human Blood Flow in a Microvascular Network. Small, 2020, 16, e2002861.	5.2	67
63	HIV Infection of monocyte-derived macrophages in vitro reduces phagocytosis of Candida albicans. Journal of Leukocyte Biology, 1994, 56, 318-327.	1.5	66
64	Comparative Evaluation of Simian, Simianâ€“Human, and Human Immunodeficiency Virus Infections in the Pigtail Macaque (Macaca nemestrina) Model. AIDS Research and Human Retroviruses, 2006, 22, 580-588.	0.5	66
65	Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques. Nature Communications, 2021, 12, 1403.	5.8	65
66	Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation. JCI Insight, 2020, 5, .	2.3	64
67	Chimeric Human Papilloma Virusâ€“Simian/Human Immunodeficiency Virus Virus-like-Particle Vaccines: Immunogenicity and Protective Efficacy in Macaques. Virology, 2002, 301, 176-187.	1.1	63
68	Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. Journal of Immunological Methods, 2012, 384, 51-61.	0.6	62
69	Age-Associated Cross-reactive Antibody-Dependent Cellular Cytotoxicity Toward 2009 Pandemic Influenza A Virus Subtype H1N1. Journal of Infectious Diseases, 2013, 208, 1051-1061.	1.9	62
70	Cross-lineage protection by human antibodies binding the influenza B hemagglutinin. Nature Communications, 2019, 10, 324.	5.8	62
71	The search for an HIV cure: tackling latent infection. Lancet Infectious Diseases, The, 2013, 13, 614-621.	4.6	61
72	Antibody-dependent cellular cytotoxicity and influenza virus. Current Opinion in Virology, 2017, 22, 89-96.	2.6	60

#	Article	IF	Citations
73	Mucosally-administered humanâ€“simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine, 2005, 23, 5009-5021.	1.7	59
74	HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV. Journal of Virology, 2017, 91, .	1.5	59
75	A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. Aids, 2006, 20, 294-297.	1.0	58
76	NK Cell Function and Antibodies Mediating ADCC in HIV-1-Infected Viremic and Controller Patients. Viral Immunology, 2011, 24, 359-368.	0.6	58
77	Cross-Reactive Influenza-Specific Antibody-Dependent Cellular Cytotoxicity in Intravenous Immunoglobulin as a Potential Therapeutic Against Emerging Influenza Viruses. Journal of Infectious Diseases, 2014, 210, 1811-1822.	1.9	57
78	Current and future nanoparticle vaccines for COVID-19. EBioMedicine, 2021, 74, 103699.	2.7	57
79	Decay of Fc-dependent antibody functions after mild to moderate COVID-19. Cell Reports Medicine, 2021, 2, 100296.	3.3	56
80	Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design. Human Vaccines and Immunotherapeutics, 2017, 13, 1288-1296.	1.4	55
81	Person-Specific Biomolecular Coronas Modulate Nanoparticle Interactions with Immune Cells in Human Blood. ACS Nano, 2020, 14, 15723-15737.	7.3	55
82	Rates of HIV immune escape and reversion: implications for vaccination. Trends in Microbiology, 2008, 16, 561-566.	3.5	53
83	Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. Journal of Virology, 2016, 90, 2021-2030.	1.5	53
84	Link between Low-Fouling and Stealth: A Whole Blood Biomolecular Corona and Cellular Association Analysis on Nanoengineered Particles. ACS Nano, 2019, 13, 4980-4991.	7.3	53
85	Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine. Journal of Virology, 2016, 90, 5724-5734.	1.5	52
86	The Utility of ADCC Responses in HIV Infection. Current HIV Research, 2008, 6, 515-519.	0.2	52
87	HIV-Specific Antibody Immunity Mediated Through NK Cells and Monocytes. Current HIV Research, 2013, 11, 388-406.	0.2	52
88	Influenza-Specific Antibody-Dependent Phagocytosis. PLoS ONE, 2016, 11, e0154461.	1.1	51
89	Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC. Journal of Immunological Methods, 2018, 457, 41-52.	0.6	51
90	HIV Infection Abrogates the Functional Advantage of Natural Killer Cells Educated through KIR3DL1/HLA-Bw4 Interactions To Mediate Anti-HIV Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2012, 86, 4488-4495.	1.5	50

#	Article	IF	Citations
91	Downregulation of Interleukin-18-Mediated Cell Signaling and Interferon Gamma Expression by the Hepatitis B Virus e Antigen. Journal of Virology, 2014, 88, 10412-10420.	1.5	49
92	Human Immunodeficiency Virus Type 1 (HIVâ€1)â€Specific T Cell Responses Correlate with Control of Acute HIVâ€1 Infection in Macaques. Journal of Infectious Diseases, 1997, 176, 1188-1197.	1.9	48
93	Comparative Efficacy of Subtype AE Simian-Human Immunodeficiency Virus Priming and Boosting Vaccines in Pigtail Macaques. Journal of Virology, 2007, 81, 292-300.	1.5	48
94	The phenotype of hepatitis B virus-specific T cells differ in the liver and blood in chronic hepatitis B virus infection. Hepatology, 2007, 46, 1332-1340.	3.6	48
95	Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN? or IL-12. Vaccine, 2004, 23, 188-197.	1.7	47
96	CD127 + CCR5 + CD38 +++ CD4 + Th1 Effector Cells Are an Early Component of the Primary Immune Response to Vaccinia Virus and Precede Development of Interleukin-2 + Memory CD4 + T Cells. Journal of Virology, 2006, 80, 10151-10161.	1.5	47
97	Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood. PLoS Pathogens, 2008, 4, e1000055.	2.1	46
98	The pigtail macaque MHC class I alleleMane-A*10presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. Journal of Medical Primatology, 2005, 34, 282-293.	0.3	45
99	Partial efficacy of a broadly neutralizing antibody against cell-associated SHIV infection. Science Translational Medicine, 2017, 9, .	5.8	45
100	Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. Journal of Virology, 2019, 93, .	1.5	44
101	Serum IgA Fc effector functions in infectious disease and cancer. Immunology and Cell Biology, 2020, 98, 276-286.	1.0	44
102	Vaccination and Timing Influence SIV Immune Escape Viral Dynamics In Vivo. PLoS Pathogens, 2008, 4, e12.	2.1	43
103	Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to â€˜protectiveâ€™ human leukocyte antigen-B alleles in HIV controllers. Aids, 2013, 27, 519-528.	1.0	43
104	Dimeric FcÎ³ Receptor Enzyme-Linked Immunosorbent Assay To Study HIV-Specific Antibodies: A New Look into Breadth of FcÎ³ Receptor Antibodies Induced by the RV144 Vaccine Trial. Journal of Immunology, 2017, 199, 816-826.	0.4	43
105	Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine, 2006, 24, 1378-1388.	1.7	42
106	Slaying the Trojan Horse: Natural Killer Cells Exhibit Robust Anti-HIV-1 Antibody-Dependent Activation and Cytolysis against Allogeneic T Cells. Journal of Virology, 2015, 89, 97-109.	1.5	42
107	Human plasma proteome association and cytotoxicity of nano-graphene oxide grafted with stealth polyethylene glycol and poly(2-ethyl-2-oxazoline). Nanoscale, 2018, 10, 10863-10875.	2.8	42
108	The protective potential of Fcâ€mediated antibody functions against influenza virus and other viral pathogens. Immunology and Cell Biology, 2020, 98, 253-263.	1.0	42

#	Article	IF	Citations
109	Block and Lock HIV Cure Strategies to Control the Latent Reservoir. Frontiers in Cellular and Infection Microbiology, 2020, 10, 424.	1.8	42
110	Standard Trivalent Influenza Virus Protein Vaccination Does Not Prime Antibody-Dependent Cellular Cytotoxicity in Macaques. Journal of Virology, 2013, 87, 13706-13718.	1.5	41
111	Polymorphisms and Interspecies Differences of the Activating and Inhibitory FcÎ³RII of Macaca nemestrina Influence the Binding of Human IgG Subclasses. Journal of Immunology, 2014, 192, 792-803.	0.4	41
112	Induction of vaginal-resident HIV-specific CD8 T cells with mucosal primeâ€“boost immunization. Mucosal Immunology, 2018, 11, 994-1007.	2.7	41
113	Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory. Nature Immunology, 2022, 23, 768-780.	7.0	41
114	Inducible Bronchus-Associated Lymphoid Tissues (iBALT) Serve as Sites of B Cell Selection and Maturation Following Influenza Infection in Mice. Frontiers in Immunology, 2019, 10, 611.	2.2	40
115	Lowâ€Fouling Fluoropolymers for Bioconjugation and Inâ€…Vivo Tracking. Angewandte Chemie - International Edition, 2020, 59, 4729-4735.	7.2	40
116	Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity. Trends in Microbiology, 2005, 13, 243-246.	3.5	39
117	Anti-HIV Antibodyâ€“Dependent Activation of NK Cells Impairs NKp46 Expression. Journal of Immunology, 2014, 192, 308-315.	0.4	39
118	Modified Vaccinia Virus Ankara Encoding Influenza Virus Hemagglutinin Induces Heterosubtypic Immunity in Macaques. Journal of Virology, 2014, 88, 13418-13428.	1.5	39
119	Fc functional antibodies in humans with severe H7N9 and seasonal influenza. JCI Insight, 2017, 2, .	2.3	39
120	A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine, 2000, 18, 2250-2256.	1.7	38
121	The testis and epididymis are productively infected by SIV and SHIV in juvenile macaques during the post-acute stage of infection. Retrovirology, 2007, 4, 7.	0.9	38
122	Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine, 2009, 27, 6605-6612.	1.7	38
123	Modulating Targeting of Poly(ethylene glycol) Particles to Tumor Cells Using Bispecific Antibodies. Advanced Healthcare Materials, 2019, 8, e1801607.	3.9	38
124	Detection of simian immunodeficiency virus (SIV)-specific CD8+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. Journal of Virology, 1996, 70, 4941-4947.	1.5	38
125	Lung-resident memory B cells established after pulmonary influenza infection display distinct transcriptional and phenotypic profiles. Science Immunology, 2022, 7, eabf5314.	5.6	38
126	The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants. Immunity, 2022, 55, 1316-1326.e4.	6.6	38

#	Article	IF	Citations
127	A Minimally Replicative HIV-2 Live-Virus Vaccine ProtectsM. nemestrinafrom Disease after HIV-2287Challenge. Virology, 1998, 242, 150-160.	1.1	37
128	MHC class I allele frequencies in pigtail macaques of diverse origin. Immunogenetics, 2006, 58, 995-1001.	1.2	37
129	Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology, 2011, 412, 110-116.	1.1	37
130	Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity. Aids, 2014, 28, 1859-1870.	1.0	37
131	Antibody-Dependent Cellular Cytotoxicity Responses to Seasonal Influenza Vaccination in Older Adults. Journal of Infectious Diseases, 2018, 217, 12-23.	1.9	37
132	Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1. Frontiers in Immunology, 2019, 10, 1025.	2.2	37
133	Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis. Aids, 1992, 6, 1169-1174.	1.0	36
134	Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine, 2005, 23, 4647-4657.	1.7	36
135	Peripheral NKT Cells in Simian Immunodeficiency Virus-Infected Macaques. Journal of Virology, 2009, 83, 1617-1624.	1.5	36
136	The High Cost of Fidelity. AIDS Research and Human Retroviruses, 2014, 30, 8-16.	0.5	36
137	MAIT Cells Upregulate Î±4Î²7 in Response to Acute Simian Immunodeficiency Virus/Simian HIV Infection but Are Resistant to Peripheral Depletion in Pigtail Macaques. Journal of Immunology, 2019, 202, 2105-2120.	0.4	36
138	Impaired Quality of the Hepatitis B Virus (HBV)-Specific T-Cell Response in Human Immunodeficiency Virus Type 1-HBV Coinfection. Journal of Virology, 2009, 83, 7649-7658.	1.5	35
139	Low pH Exposure During Immunoglobulin G Purification Methods Results in Aggregates That Avidly Bind FcÎ³ Receptors: Implications for Measuring Fc Dependent Antibody Functions. Frontiers in Immunology, 2019, 10, 2415.	2.2	35
140	Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain. Cell Reports, 2021, 37, 109822.	2.9	35
141	Stealth nanorods via the aqueous living crystallisation-driven self-assembly of poly(2-oxazoline)s. Chemical Science, 2021, 12, 7350-7360.	3.7	35
142	Vaccine-Induced T Cells Control Reversion of AIDS Virus Immune Escape Mutants. Journal of Virology, 2007, 81, 4137-4144.	1.5	34
143	Activation of NK Cells by ADCC Responses During Early HIV Infection. Viral Immunology, 2011, 24, 171-175.	0.6	34
144	Replication-Competent Simian Immunodeficiency Virus (SIV) Gag Escape Mutations Archived in Latent Reservoirs during Antiretroviral Treatment of SIV-Infected Macaques. Journal of Virology, 2011, 85, 9167-9175.	1.5	34

#	Article	IF	Citations
145	NKT cell depletion in humans during early HIV infection. Immunology and Cell Biology, 2014, 92, 578-590.	1.0	34
146	The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial. Lancet HIV,the, 2018, 5, e221-e230.	2.1	34
147	Immune cellular networks underlying recovery from influenza virus infection in acute hospitalized patients. Nature Communications, 2021, 12, 2691.	5.8	34
148	Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways. Journal of Virology, 2019, 93, .	1.5	33
149	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight, 2021, 6, .	2.3	33
150	Prime-Boost Strategies in DNA Vaccines. , 2006, 127, 171-198.		32
151	The role of HIV-specific antibody-dependent cellular cytotoxicity in HIV prevention and the influence of the HIV-1 Vpu protein. Aids, 2015, 29, 137-144.	1.0	32
152	HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation. Scientific Reports, 2016, 6, 26478.	1.6	32
153	Importance of Fc-mediated functions of anti-HIV-1 broadly neutralizing antibodies. Retrovirology, 2018, 15, 58.	0.9	32
154	High CD26 and Low CD94 Expression Identifies an IL-23 Responsive VÎ´2+ T Cell Subset with a MAIT Cell-like Transcriptional Profile. Cell Reports, 2020, 31, 107773.	2.9	32
155	Vaccination with Attenuated Simian Immunodeficiency Virus by DNA Inoculation. Journal of Virology, 2001, 75, 11930-11934.	1.5	31
156	Evaluation of Recombinant Influenza Virus-Simian Immunodeficiency Virus Vaccines in Macaques. Journal of Virology, 2009, 83, 7619-7628.	1.5	31
157	Human immune cell targeting of protein nanoparticles â€“ caveospheres. Nanoscale, 2016, 8, 8255-8265.	2.8	31
158	NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity. AIDS Research and Human Retroviruses, 2016, 32, 1089-1096.	0.5	31
159	Enhanced Cellular Immunity in Macaques following a Novel Peptide Immunotherapy. Journal of Virology, 2005, 79, 3748-3757.	1.5	30
160	Killing Kinetics of Simian Immunodeficiency Virus-Specific CD8+ T Cells: Implications for HIV Vaccine Strategies. Journal of Immunology, 2007, 179, 4571-4579.	0.4	30
161	Does Cytolysis by CD8+ T Cells Drive Immune Escape in HIV Infection?. Journal of Immunology, 2010, 185, 5093-5101.	0.4	30
162	Enhancing dendritic cell activation and HIV vaccine effectiveness through nanoparticle vaccination. Expert Review of Vaccines, 2016, 15, 719-729.	2.0	30

#	Article	IF	Citations
163	Intravenous Immunoglobulin Protects Against Severe Pandemic Influenza Infection. EBioMedicine, 2017, 19, 119-127.	2.7	30
164	Controlling the Biological Fate of Micellar Nanoparticles: Balancing Stealth and Targeting. ACS Nano, 2020, 14, 13739-13753.	7.3	30
165	Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine, 2005, 23, 1949-1956.	1.7	29
166	In Vivo Fitness Costs of Different Gag CD8 T-Cell Escape Mutant Simian-Human Immunodeficiency Viruses for Macaques. Journal of Virology, 2007, 81, 5418-5422.	1.5	29
167	Virus-Specific T-Cell Immunity Correlates with Control of GB Virus B Infection in Marmosets. Journal of Virology, 2008, 82, 3054-3060.	1.5	29
168	Screening and confirmatory testing of MHC class I alleles in pig-tailed macaques. Immunogenetics, 2011, 63, 511-521.	1.2	29
169	HIVâ€specific antibodyâ€dependent phagocytosis matures during HIV infection. Immunology and Cell Biology, 2014, 92, 679-687.	1.0	29
170	Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina.. Journal of Clinical Investigation, 1995, 95, 248-256.	3.9	29
171	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 2021, 74, 103729.	2.7	29
172	Utility of Human Immunodeficiency Virus Type 1 Envelope as a T-Cell Immunogen. Journal of Virology, 2007, 81, 13125-13134.	1.5	28
173	Characterisation of macaque testicular leucocyte populations and T-lymphocyte immunity. Journal of Reproductive Immunology, 2013, 100, 146-156.	0.8	28
174	Antibody-Dependent Effector Functions Against HIV Decline in Subjects Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2015, 211, 529-538.	1.9	28
175	The primary immune response to Vaccinia virus vaccination includes cells with a distinct cytotoxic effector CD4 T-cell phenotype. Vaccine, 2016, 34, 5251-5261.	1.7	28
176	Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field. Current HIV Research, 2017, 15, 202-215.	0.2	28
177	Improving immunological insights into the ferret model of human viral infectious disease. Influenza and Other Respiratory Viruses, 2019, 13, 535-546.	1.5	28
178	Robust correlations across six SARSâ€CoVâ€2 serology assays detecting distinct antibody features. Clinical and Translational Immunology, 2021, 10, e1258.	1.7	28
179	SARSâ€CoVâ€2â€specific CD8⁺ Tâ€cell responses and TCR signatures in the context of a prominent HLAâ€A*24:02 allomorph. Immunology and Cell Biology, 2021, 99, 990-1000.	1.0	28
180	HIV-1 infection of monocyte-derived macrophages reduces Fc and complement receptor expression. Clinical and Experimental Immunology, 2008, 95, 450-454.	1.1	27

#	Article	IF	Citations
181	Charge Has a Marked Influence on Hyperbranched Polymer Nanoparticle Association in Whole Human Blood. ACS Macro Letters, 2017, 6, 586-592.	2.3	27
182	Perturbation of mucosal-associated invariant T cells and iNKT cells in HIV infection. Current Opinion in HIV and AIDS, 2019, 14, 77-84.	1.5	27
183	Hemagglutinin Functionalized Liposomal Vaccines Enhance Germinal Center and Follicular Helper T Cell Immunity. Advanced Healthcare Materials, 2021, 10, e2002142.	3.9	27
184	Influence of Poly(ethylene glycol) Molecular Architecture on Particle Assembly and Ex Vivo Particleâ€“Immune Cell Interactions in Human Blood. ACS Nano, 2021, 15, 10025-10038.	7.3	27
185	HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells. Frontiers in Immunology, 2017, 8, 376.	2.2	26
186	Interactions of core cross-linked poly(2-oxazoline) and poly(2-oxazine) micelles with immune cells in human blood. Biomaterials, 2021, 274, 120843.	5.7	26
187	Anti-HIV-1 antibody-dependent cellular cytotoxicity. Current Opinion in HIV and AIDS, 2018, 13, 160-166.	1.5	25
188	Templateâ€Mediated Assembly of DNA into Microcapsules for Immunological Modulation. Small, 2020, 16, e2002750.	5.2	25
189	T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination. Journal of Leukocyte Biology, 2022, 111, 355-365.	1.5	25
190	Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?. Frontiers in Immunology, 2015, 6, 265.	2.2	24
191	Thiol-Reactive Star Polymers Display Enhanced Association with Distinct Human Blood Components. ACS Applied Materials & Interfaces, 2017, 9, 12182-12194.	4.0	24
192	Characterization of the Kynurenine Pathway and Quinolinic Acid Production in Macaque Macrophages. International Journal of Tryptophan Research, 2013, 6, IJTR.S11789.	1.0	23
193	Identification of Native and Posttranslationally Modified HLAâ€B*57:01â€Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. Proteomics, 2018, 18, e1700253.	1.3	23
194	Influence of Charge on Hemocompatibility and Immunoreactivity of Polymeric Nanoparticles. ACS Applied Bio Materials, 2018, 1, 756-767.	2.3	23
195	SARS-CoV-2-specific TÂcell memory with common TCRÎ±Î² motifs is established in unvaccinated children who seroconvert after infection. Immunity, 2022, 55, 1299-1315.e4.	6.6	23
196	Vaccines and Vaccine Strategies Against HIV. Current Drug Targets, 2004, 5, 71-88.	1.0	22
197	HIV Vaccine efficacy trial: Glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity. Hum Vaccin, 2011, 7, 466-473.	2.4	22
198	Antiâ€<scp>HIV</scp>â€1 antibodyâ€dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum <scp>Ig</scp>G</scp>. European Journal of Immunology, 2012, 42, 2771-2781.	1.6	22

#	Article	IF	Citations
199	Influence of Cytokines on HIV-Specific Antibody-Dependent Cellular Cytotoxicity Activation Profile of Natural Killer Cells. PLoS ONE, 2012, 7, e38580.	1.1	22
200	Serial study of lymph node cell subsets using fine needle aspiration in pigtail macaques. Journal of Immunological Methods, 2013, 394, 73-83.	0.6	22
201	Indian Long-term Non-Progressors Show Broad ADCC Responses with Preferential Recognition of V3 Region of Envelope and a Region from Tat Protein. Frontiers in Immunology, 2017, 8, 5.	2.2	22
202	The Multifaceted Nature of Immunoglobulin A and Its Complex Role in HIV. AIDS Research and Human Retroviruses, 2018, 34, 727-738.	0.5	22
203	Lowâ€Fouling Fluoropolymers for Bioconjugation and Inâ€…Vivo Tracking. Angewandte Chemie, 2020, 132, 4759-4765.	1.6	22
204	Induction of T-Cell Immunity to Antiretroviral Drug-Resistant Human Immunodeficiency Virus Type 1. Journal of Virology, 2005, 79, 7728-7737.	1.5	21
205	Evaluation of recombinant Kunjin replicon SIV vaccines for protective efficacy in macaques. Virology, 2008, 374, 528-534.	1.1	21
206	CD4+ Target Cell Availability Determines the Dynamics of Immune Escape and Reversion In Vivo. Journal of Virology, 2008, 82, 4091-4101.	1.5	21
207	Natural Host Genetic Resistance to Lentiviral CNS Disease: A Neuroprotective MHC Class I Allele in SIV-Infected Macaques. PLoS ONE, 2008, 3, e3603.	1.1	21
208	An â€œEscape Clockâ€•for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells. PLoS Pathogens, 2012, 8, e1002615.	2.1	21
209	Ex-vivo Î±-Galactosylceramide activation of NKT cells in humans and macaques. Journal of Immunological Methods, 2012, 382, 150-159.	0.6	21
210	Linking Pig-Tailed Macaque Major Histocompatibility Complex Class I Haplotypes and Cytotoxic T Lymphocyte Escape Mutations in Simian Immunodeficiency Virus Infection. Journal of Virology, 2014, 88, 14310-14325.	1.5	21
211	Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. Journal of Virology, 2017, 91, .	1.5	21
212	Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5â€“8 Days. PLoS Pathogens, 2016, 12, e1005740.	2.1	21
213	Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma. Journal of Medical Primatology, 2003, 29, 240-247.	0.3	20
214	Antibody-Dependent Cellular Cytotoxicity and NK Cell-Driven Immune Escape in HIV Infection: Implications for HIV Vaccine Development. Advances in Virology, 2012, 2012, 1-8.	0.5	20
215	Role of education and differentiation in determining the potential of natural killer cells to respond to antibody-dependent stimulation. Aids, 2014, 28, 2781-2786.	1.0	20
216	A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens. Frontiers in Immunology, 2017, 8, 595.	2.2	20

#	Article	IF	Citations
217	Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein. Journal of Biological Chemistry, 2021, 297, 101065.	1.6	20
218	Modeling the Timing of Antilatency Drug Administration during HIV Treatment. Journal of Virology, 2014, 88, 14050-14056.	1.5	19
219	Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2018, 5, e553-e559.	2.1	19
220	Analysis of Cytotoxic T Lymphocyte Responses to SIV Proteins in SIV-Infected Macaques Using Antigen-Specific Stimulation with Recombinant Vaccinia and Fowl Poxviruses. AIDS Research and Human Retroviruses, 1994, 10, 551-560.	0.5	18
221	Decreased Neurotropism of nef Long Terminal Repeat (nef /LTR)-Deleted Simian Immunodeficiency Virus. Journal of NeuroVirology, 2003, 9, 442-451.	1.0	18
222	Phenotypical and functional profiles of natural killer cells exhibiting matrix metalloproteinase-mediated CD16 cleavage after anti-HIV antibody-dependent activation. Clinical and Experimental Immunology, 2015, 181, 275-285.	1.1	18
223	Cutaneous mucormycosis secondary to penetrative trauma. Injury, 2016, 47, 1383-1387.	0.7	18
224	Tuning the properties of pH responsive nanoparticles to control cellular interactions in vitro and ex vivo. Polymer Chemistry, 2016, 7, 6015-6024.	1.9	18
225	Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution. ACS Applied Materials & Interfaces, 2017, 9, 33683-33694.	4.0	18
226	Developing a multivariate prediction model of antibody features associated with protection of malaria-infected pregnant women from placental malaria. ELife, 2021, 10, .	2.8	18
227	Obstacles to ideal anti-HIV antibody-dependent cellular cytotoxicity responses. Vaccine, 2013, 31, 5506-5517.	1.7	17
228	Trivalent Live Attenuated Influenza-Simian Immunodeficiency Virus Vaccines: Efficacy and Evolution of Cytotoxic T Lymphocyte Escape in Macaques. Journal of Virology, 2013, 87, 4146-4160.	1.5	17
229	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 17-23.	0.9	17
230	Functional advantage of educated KIR2DL1+ natural killer cells for anti-HIV-1 antibody-dependent activation. Clinical and Experimental Immunology, 2016, 184, 101-109.	1.1	17
231	Contribution of NK Cell Education to both Direct and Anti-HIV-1 Antibody-Dependent NK Cell Functions. Journal of Virology, 2018, 92, .	1.5	17
232	Mucosal-Associated Invariant T Cells Are Depleted and Exhibit Altered Chemokine Receptor Expression and Elevated Granulocyte Macrophage-Colony Stimulating Factor Production During End-Stage Renal Disease. Frontiers in Immunology, 2018, 9, 1076.	2.2	17
233	An Inflammatory Story: Antibodies in Tuberculosis Comorbidities. Frontiers in Immunology, 2019, 10, 2846.	2.2	17
234	Thrombocytopenia Is Strongly Associated With Simian AIDS in Pigtail Macaques. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 374-379.	0.9	16

#	Article	IF	Citations
235	Loss of Control of HIV Viremia Associated with the Fat Malabsorption Drug Orlistat. AIDS Research and Human Retroviruses, 2012, 28, 961-962.	0.5	16
236	Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity. Expert Review of Vaccines, 2015, 14, 1227-1239.	2.0	16
237	Antibody-dependent phagocytosis (ADP) responses following trivalent inactivated influenza vaccination of younger and older adults. Vaccine, 2017, 35, 6451-6458.	1.7	16
238	Differential Roles of Plasma Protein Corona on Immune Cell Association and Cytokine Secretion of Oligomeric and Fibrillar Beta-Amyloid. Biomacromolecules, 2019, 20, 4208-4217.	2.6	16
239	What Can Gamma Delta T Cells Contribute to an HIV Cure?. Frontiers in Cellular and Infection Microbiology, 2020, 10, 233.	1.8	16
240	Adaptive immunity to human coronaviruses is widespread but low in magnitude. Clinical and Translational Immunology, 2021, 10, e1264.	1.7	16
241	Fitness Constraints on Immune Escape from HIV: Implications of Envelope as a Target for Both HIV-Specific T Cells and Antibody. Current HIV Research, 2006, 4, 191-197.	0.2	15
242	Simian immunodeficiency virus infection and immune responses in the pig-tailed macaque testis. Journal of Leukocyte Biology, 2015, 97, 599-609.	1.5	15
243	Identification of murine antigen-specific T follicular helper cells using an activation-induced marker assay. Journal of Immunological Methods, 2019, 467, 48-57.	0.6	15
244	Tear antibodies to SARSâ€CoVâ€2: implications for transmission. Clinical and Translational Immunology, 2021, 10, e1354.	1.7	15
245	Granulocyte contamination dramatically inhibits spot formation in AIDS virus-specific ELISpot assays: Analysis and strategies to ameliorate. Journal of Immunological Methods, 2005, 297, 177-186.	0.6	14
246	Inactivated Simian Immunodeficiency Virus-Pulsed Autologous Fresh Blood Cells as an Immunotherapy Strategy. Journal of Virology, 2009, 83, 1501-1510.	1.5	14
247	In-vivo stimulation of macaque natural killer T cells with Î±-galactosylceramide. Clinical and Experimental Immunology, 2013, 173, 480-492.	1.1	14
248	Activation of NK cells by HIV-specific ADCC antibodies. Human Vaccines and Immunotherapeutics, 2013, 9, 1011-1018.	1.4	14
249	Recombinant influenza virus expressing HIV-1 p24 capsid protein induces mucosal HIV-specific CD8 T-cell responses. Vaccine, 2016, 34, 1172-1179.	1.7	14
250	Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption. Journal of Virology, 2017, 91, .	1.5	14
251	Mucosal and systemic SIV-specific cytotoxic CD4+ T cell hierarchy in protection following intranasal/intramuscular recombinant pox-viral vaccination of pigtail macaques. Scientific Reports, 2019, 9, 5661.	1.6	14
252	Induction of SerpinB2 and Th1/Th2 Modulation by SerpinB2 during Lentiviral Infections In Vivo. PLoS ONE, 2013, 8, e57343.	1.1	14

#	Article	IF	Citations
253	Nucleic Acid Vaccines Tasks and Tactics. Immunologic Research, 2001, 24, 225-244.	1.3	13
254	Dose-Response Relationship of DNA and Recombinant Fowlpox Virus Prime-Boost HIV Vaccines: Implications for Future Trials. Hum Vaccin, 2006, 2, 134-136.	2.4	13
255	Limited Maintenance of Vaccine-Induced Simian Immunodeficiency Virus-Specific CD8 T-Cell Receptor Clonotypes after Virus Challenge. Journal of Virology, 2008, 82, 7357-7368.	1.5	13
256	Timing of Immune Escape Linked to Success or Failure of Vaccination. PLoS ONE, 2010, 5, e12774.	1.1	13
257	The role of T cell immunity in HIV-1 infection. Current Opinion in Virology, 2013, 3, 438-446.	2.6	13
258	Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination. Frontiers in Immunology, 2017, 8, 1883.	2.2	13
259	Modulation of innate and adaptive cellular immunity relevant to HIV-1 vaccine design by seminal plasma. Aids, 2017, 31, 333-342.	1.0	13
260	Low pre-infection levels and loss of central memory CD4+ T cells may predict rapid progression in SIV-infected pigtail macaques. Virology, 2008, 381, 11-15.	1.1	12
261	Safety, immunogenicity and efficacy of peptideâ€pulsed cellular immunotherapy in macaques. Journal of Medical Primatology, 2008, 37, 69-78.	0.3	12
262	AIDS Vaccine for Asia Network (AVAN): Expanding the Regional Role in Developing HIV Vaccines. PLoS Medicine, 2010, 7, e1000331.	3.9	12
263	Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 345-353.	0.9	12
264	A Lipid/DNA Adjuvantâ€“Inactivated Influenza Virus Vaccine Protects Rhesus Macaques From Uncontrolled Virus Replication After Heterosubtypic Influenza A Virus Challenge. Journal of Infectious Diseases, 2018, 218, 856-867.	1.9	12
265	Evidence of Recombination between 3â€² and 5â€² LTRs in Macaques Inoculated with SIV DNA. AIDS Research and Human Retroviruses, 2002, 18, 227-230.	0.5	11
266	Lipopolysaccharide induces biochemical alterations in chicks trained on the passive avoidance learning task. Physiology and Behavior, 2003, 78, 679-688.	1.0	11
267	Quantification of Simian Immunodeficiency Virus Cytotoxic T Lymphocyte Escape Mutant Viruses. AIDS Research and Human Retroviruses, 2008, 24, 1067-1072.	0.5	11
268	Substantial envelope-specific CD8 T-cell immunity fails to control siv disease. Virology, 2009, 384, 21-27.	1.1	11
269	Divergent Expression of CXCR5 and CCR5 on CD4+ T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection. Frontiers in Immunology, 2017, 8, 495.	2.2	11
270	Characterization of Key Bioâ€“Nano Interactions between Organosilica Nanoparticles and Candida albicans. ACS Applied Materials & Interfaces, 2019, 11, 34676-34687.	4.0	11

#	Article	IF	Citations
271	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2019, 93, .	1.5	11
272	Modulating the Selectivity and Stealth Properties of Ellipsoidal Polymersomes through a Multivalent Peptide Ligand Display. Advanced Healthcare Materials, 2020, 9, e2000261.	3.9	11
273	Antibody mediated activation of natural killer cells in malaria exposed pregnant women. Scientific Reports, 2021, 11, 4130.	1.6	11
274	Complexity of the Inoculum Determines the Rate of Reversion of SIV Gag CD8 T Cell Mutant Virus and Outcome of Infection. PLoS Pathogens, 2009, 5, e1000378.	2.1	10
275	Differential patterns of immune escape at Tat-specific cytotoxic T cell epitopes in pigtail macaques. Virology, 2009, 388, 315-323.	1.1	10
276	Comparison of Influenza and SIV Specific CD8 T Cell Responses in Macaques. PLoS ONE, 2012, 7, e32431.	1.1	10
277	Central nervous system-specific consequences of simian immunodeficiency virus Gag escape from major histocompatibility complex class I-mediated control. Journal of NeuroVirology, 2016, 22, 498-507.	1.0	10
278	High fidelity simian immunodeficiency virus reverse transcriptase mutants have impaired replication in vitro and in vivo. Virology, 2016, 492, 1-10.	1.1	10
279	Impact of alemtuzumab on HIV persistence in an HIV-infected individual on antiretroviral therapy with Sezary syndrome. Aids, 2017, 31, 1839-1845.	1.0	10
280	Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission?. Journal of Virology, 2017, 91, .	1.5	10
281	Meibomian gland dropout is associated with immunodeficiency at HIV diagnosis: Implications for dry eye disease. Ocular Surface, 2020, 18, 206-213.	2.2	10
282	Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults. Vaccine, 2020, 38, 2368-2377.	1.7	10
283	Vaccination after prior COVID-19 infection: Implications for dose sparing and booster shots. EBioMedicine, 2021, 72, 103586.	2.7	10
284	Measuring Turnover of SIV DNA in Resting CD4+ T Cells Using Pyrosequencing: Implications for the Timing of HIV Eradication Therapies. PLoS ONE, 2014, 9, e93330.	1.1	10
285	Attenuated and Wild-Type HIV-1 Infections and Long Terminal Repeat-Mediated Gene Expression from Plasmids Delivered by Gene Gun to Human Skin ex Vivo and Macaques in Vivo. Virology, 2001, 287, 71-78.	1.1	9
286	Delivery of immunotherapy with peptide-pulsed blood in macaques. Virology, 2008, 378, 201-204.	1.1	9
287	Epitope-Specific CD8+T Cell Kinetics Rather than Viral Variability Determine the Timing of Immune Escape in Simian Immunodeficiency Virus Infection. Journal of Immunology, 2015, 194, 4112-4121.	0.4	9
288	Quantitatively Tracking Bioâ€“Nano Interactions of Metalâ€“Phenolic Nanocapsules by Mass Cytometry. ACS Applied Materials & Interfaces, 2021, 13, 35494-35505.	4.0	9

#	Article	IF	Citations
289	Poor protective potential of influenza nucleoprotein antibodies despite wide prevalence. Immunology and Cell Biology, 2022, 100, 49-60.	1.0	9
290	Protein precoating modulates biomolecular coronas and nanocapsuleâ€“immune cell interactions in human blood. Journal of Materials Chemistry B, 2022, 10, 7607-7621.	2.9	9
291	Comparison of Whole Gene and Whole Virus Scrambled Antigen Approaches for DNA Prime and Fowlpox Virus Boost HIV Type 1 Vaccine Regimens in Macaques. AIDS Research and Human Retroviruses, 2005, 21, 292-300.	0.5	8
292	Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection. Journal of Infectious Diseases, 2018, 218, 1383-1393.	1.9	8
293	A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination. Cell Reports Medicine, 2021, 2, 100386.	3.3	8
294	Serological and cellular inflammatory signatures in endâ€stage kidney disease and latent tuberculosis. Clinical and Translational Immunology, 2021, 10, e1355.	1.7	8
295	Drug evaluation: DNA/MVA prime-boost HIV vaccine. Current Opinion in Investigational Drugs, 2007, 8, 159-67.	2.3	8
296	Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques. Immunological Reviews, 2001, 183, 94-108.	2.8	7
297	HIV-specific antibody-dependent cellular cytotoxicity: a novel vaccine modality. Expert Review of Clinical Immunology, 2012, 8, 767-774.	1.3	7
298	The Rare Anaphylaxis-Associated FcÎ³RIIa3 Exhibits Distinct Characteristics From the Canonical FcÎ³RIIa1. Frontiers in Immunology, 2018, 9, 1809.	2.2	7
299	Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Viruses, 2018, 10, 333.	1.5	7
300	Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine. Human Gene Therapy, 2018, 29, 1011-1028.	1.4	7
301	Innate and Adaptive Anti-SIV Responses in Macaque Semen: Implications for Infectivity and Risk of Transmission. Frontiers in Immunology, 2020, 11, 850.	2.2	7
302	Mucosal IL-4R antagonist HIV vaccination with SOSIP-gp140 booster can induce high-quality cytotoxic CD4+/CD8+ T cells and humoral responses in macaques. Scientific Reports, 2020, 10, 22077.	1.6	7
303	Genetic influences on HIV infection: implications for vaccine development. Sexual Health, 2005, 2, 53.	0.4	7
304	The maturation of antibody technology for the HIV epidemic. Immunology and Cell Biology, 2014, 92, 570-577.	1.0	6
305	HIV Reactivation after Partial Protection by Neutralizing Antibodies. Trends in Immunology, 2018, 39, 359-366.	2.9	6
306	Immune profiling of influenzaâ€specific Bâ€•and Tâ€cell responses in macaques using flow cytometryâ€based assays. Immunology and Cell Biology, 2021, 99, 97-106.	1.0	6

#	Article	IF	Citations
307	Coformulation with Tattoo Ink for Immunological Assessment of Vaccine Immunogenicity in the Draining Lymph Node. Journal of Immunology, 2021, 207, 735-744.	0.4	6
308	Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil. Journal of Immunology, 2022, , ji2101199.	0.4	6
309	Understanding the Role of Mucosal-Associated Invariant T-Cells in Non-human Primate Models of HIV Infection. Frontiers in Immunology, 2020, 11, 2038.	2.2	5
310	Sequencing B cell receptors from ferrets (Mustela putorius furo). PLoS ONE, 2020, 15, e0233794.	1.1	5
311	Genetically identical primate modelling systems for HIV vaccines. Reproduction, Fertility and Development, 1998, 10, 651.	0.1	5
312	CD4+T-cell subsets: what really counts in preventing HIV disease?. Expert Review of Vaccines, 2008, 7, 155-158.	2.0	4
313	Characterisation of simian immunodeficiency virus-infected cells in pigtail macaques. Virology, 2012, 428, 11-20.	1.1	4
314	Short Communication: Antibody Responses to Human Immunodeficiency Virus Envelope from Infections with Multiple Subtypes Utilize the 1F7-Idiotypic Repertoire. AIDS Research and Human Retroviruses, 2013, 29, 778-783.	0.5	4
315	Ageing in patients with chronic HIV infection: impact of hypercoagulation. AIDS Research and Therapy, 2018, 15, 22.	0.7	4
316	Plasma Corona Protects Human Immune Cells from Structurally Nanoengineered Antimicrobial Peptide Polymers. ACS Applied Materials & Interfaces, 2021, 13, 33821-33829.	4.0	4
317	Screening and development of monoclonal antibodies for identification of ferret T follicular helper cells. Scientific Reports, 2021, 11, 1864.	1.6	4
318	Robust and prototypical immune responses toward influenza vaccines in the high-risk group of Indigenous Australians. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	4
319	Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121. Frontiers in Immunology, 2021, 12, 749891.	2.2	4
320	Can HIV Infection be Prevented with a Vaccine?. Drugs in R and D, 1999, 1, 431-440.	1.1	3
321	Vaccines for HIV. Expert Opinion on Therapeutic Patents, 2000, 10, 1179-1188.	2.4	3
322	Protection afforded by live attenuated SIV is associated with rapid killing kinetics of CTLs. Journal of Medical Primatology, 2008, 37, 24-32.	0.3	3
323	Short Communication: Effect of Seminal Plasma on Functions of Monocytes and Granulocytes. AIDS Research and Human Retroviruses, 2019, 35, 553-556.	0.5	3
324	Modulation of the CCR5 Receptor/Ligand Axis by Seminal Plasma and the Utility of In Vitro versus In Vivo Models. Journal of Virology, 2019, 93, .	1.5	3

#	Article	IF	Citations
325	Influenza B viruses: underestimated and overlooked. Microbiology Australia, 2021, 42, 110-115.	0.1	3
326	Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure. EBioMedicine, 2021, 70, 103518.	2.7	3
327	Contemporary HIV Vaccines: Tissue Resident T-Cells and Strategies to Prevent Mucosal Infection. Current Topics in Medicinal Chemistry, 2015, 16, 1107-1117.	1.0	3
328	8.3 Prospects for a preventive HIV vaccine. Medical Journal of Australia, 1996, 165, 212-215.	0.8	2
329	Preventive HIV-1 vaccines: where are we going?. International Journal of STD and AIDS, 1998, 9, 715-719.	0.5	2
330	Phenotypic and kinetic analysis of effective simianâ€“human immunodeficiency virus-specific T cell responses in DNA- and fowlpox virus-vaccinated macaques. Virology, 2005, 337, 222-234.	1.1	2
331	Balancing Reversion of Cytotoxic T-Lymphocyte and Neutralizing Antibody Escape Mutations within Human Immunodeficiency Virus Type 1 Env upon Transmission. Journal of Virology, 2009, 83, 8986-8992.	1.5	2
332	P17-03. Nanoengineered layer-by-layer capsules as a novel delivery system for HIV vaccines. Retrovirology, 2009, 6, .	0.9	2
333	Toward Improved Influenza Vaccines. Journal of Infectious Diseases, 2014, 209, 4-5.	1.9	2
334	CD73+ CD127high Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection. International Journal of Molecular Sciences, 2021, 22, 912.	1.8	2
335	Azithromycin: more lethal than chloramphenicol?. Sexual Health, 2013, 10, 179.	0.4	2
336	Re: Integrated Immune Dynamics Define Correlates of COVID-19 Severity and Antibody Responses. SSRN Electronic Journal, 0, , .	0.4	2
337	Listeria monocytogenes peritonitis with review of literature. Australian and New Zealand Journal of Medicine, 1994, 24, 405-405.	0.5	1
338	Simian immunodeficiency virus infections in vervet monkeys (Clorocebus aethiops) at an Australian zoo. Australian Veterinary Journal, 2001, 79, 406-408.	0.5	1
339	Short Communication: Characteristics of Effective Immune Control of Simian/Human Immunodeficiency Virus in Pigtail Macaques. AIDS Research and Human Retroviruses, 2006, 22, 27-32.	0.5	1
340	P10-07. Extremely rapid degranulation of NK cells activated by HIV-specific antibody dependent cellular cytotoxicity. Retrovirology, 2009, 6, .	0.9	1
341	Tentative first steps to eradicate latent HIV. Lancet HIV,the, 2014, 1, e2-e3.	2.1	1
342	Prime-Boost Vaccination: Impact on the HIV-1 Vaccine Field. , 2015, , 289-313.		1

#	Article	IF	Citations
343	Twist in the Tail: Escape from HIV Neutralising Antibodies at a Single Site Confers Broad Susceptibility to Others. EBioMedicine, 2016, 12, 14-15.	2.7	1
344	Expanding role for type I Interferons in restricting HIV growth. Immunology and Cell Biology, 2017, 95, 417-418.	1.0	1
345	Exploration of broadly neutralizing antibody fragments produced in bacteria for the control of HIV. Human Vaccines and Immunotherapeutics, 2017, 13, 2726-2737.	1.4	1
346	A Role for Fc-Mediated Humoral Immunity in Reducing HIV Transmission Rates between HIV Serodiscordant Heterosexual Couples. EBioMedicine, 2017, 26, 2-3.	2.7	1
347	Moving the HIV vaccine field forward: concepts of protective immunity. Lancet HIV,the, 2019, 6, e406-e410.	2.1	1
348	Boosting of Markers of FcÎ³ Receptor Function in Anti-HIV Antibodies During Structured Treatment Interruption. AIDS Research and Human Retroviruses, 2019, 35, 842-852.	0.5	1
349	Impact of HIVâ€1 viremia or sexually transmitted infection on semenâ€derived antiâ€HIVâ€1 antibodies and the immunosuppressive capacity of seminal plasma. European Journal of Immunology, 2019, 49, 2255-2258.	1.6	1
350	Cellular Interactions: Cellular Interactions of Liposomes and PISA Nanoparticles during Human Blood Flow in a Microvascular Network (Small 33/2020). Small, 2020, 16, 2070185.	5.2	1
351	Aggregation by peptide conjugation rescues poor immunogenicity of the HA stem. PLoS ONE, 2020, 15, e0241649.	1.1	1
352	A Quantitative Approach to Unravel the Role of Host Genetics in IgG-FcÎ³R Complex Formation After Vaccination. Frontiers in Immunology, 2022, 13, 820148.	2.2	1
353	HIV vaccines â€" promise and directions:Cooperative research will be good for Australia and the world. Medical Journal of Australia, 1999, 171, 124-125.	0.8	0
354	Vaccines for HIV in the developing world. Internal Medicine Journal, 2002, 32, 136-137.	0.5	0
355	Anti-SIV Cytolytic Molecules in Pigtail Macaques. AIDS Research and Human Retroviruses, 2008, 24, 1127-1131.	0.5	0
356	P19-24. Evaluation of recombinant influenza-SIV vaccines in macaques. Retrovirology, 2009, 6, .	0.9	0
357	P09-08. The complexity of the infecting inoculum determines the outcome of infection. Retrovirology, 2009, 6, P121.	0.9	0
358	P09-07. Balancing reversion of CTL and neutralizing antibody escape mutations within HIV-1 Env upon transmission. Retrovirology, 2009, 6, .	0.9	0
359	Designing immunity to HIV: manipulating antibody-dependent cellular cytotoxicity antibodies. HIV Therapy, 2009, 3, 633-640.	0.6	0
360	Drug Resistant SIV Strains Carrying Higher-Fidelity K65R and Q151N Reverse Transcriptase Mutations Are Less Fit In Vivo. AIDS Research and Human Retroviruses, 2014, 30, A185-A185.	0.5	0

#	Article	IF	Citations
361	Paradox of Protection: Preferential Recognition of CD4-induced Epitopes by Anti-HIV-1 ADCC Antibodies. EBioMedicine, 2015, 2, 1298-1299.	2.7	0
362	Trying to cure HIV with immunotherapy: not so simple. Lancet HIV,the, 2015, 2, e72-e73.	2.1	0
363	Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 253-259.	1.3	0
364	HIV vaccines moving forward. Current Opinion in HIV and AIDS, 2016, 11, 545.	1.5	0
365	Eradication and Cure of HIV. , 2017, , 931-935.e1.		0
366	The future of mucosal HIV vaccines. Microbiology Australia, 2011, 32, 118.	0.1	0
367	High Precursor Frequency and Promiscuity in Î²2 T Cell Receptor Pairing Underpin CD8+ T-Cell Responses to an Immunodominant SARS-CoV-2 Nucleocapsid Epitope. SSRN Electronic Journal, 0, , .	0.4	0
368	Sequencing B cell receptors from ferrets (Mustela putorius furo). , 2020, 15, e0233794.		0
369	Sequencing B cell receptors from ferrets (Mustela putorius furo). , 2020, 15, e0233794.		0
370	Sequencing B cell receptors from ferrets (Mustela putorius furo). , 2020, 15, e0233794.		0
371	Sequencing B cell receptors from ferrets (Mustela putorius furo). , 2020, 15, e0233794.		0